Pulmonary Fibrosis Clinical Trials

27 recruiting

Pulmonary Fibrosis Trials at a Glance

98 actively recruiting trials for pulmonary fibrosis are listed on ClinicalTrialsFinder across 6 cities in 50 countries. The largest study group is Phase 2 with 26 trials, with the heaviest enrollment activity in Los Angeles, Kansas City, and Charleston. Lead sponsors running pulmonary fibrosis studies include Avalyn Pharma Inc., Boehringer Ingelheim, and Erasmus Medical Center.

Browse pulmonary fibrosis trials by phase

Treatments under study

About Pulmonary Fibrosis Clinical Trials

Looking for clinical trials for Pulmonary Fibrosis? There are currently 27 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pulmonary Fibrosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pulmonary Fibrosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 98 trials

Recruiting
Phase 2

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim20 enrolled3 locationsNCT06241560
Recruiting
Phase 2

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim71 enrolled47 locationsNCT07036523
Recruiting
Phase 3

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis
Boehringer Ingelheim1,700 enrolled371 locationsNCT06238622
Recruiting
Phase 3

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

Interstitial Lung DiseasesFamilial Pulmonary FibrosisInterstitial Lung Abnormalities
Boehringer Ingelheim80 enrolled56 locationsNCT07201922
Recruiting
Not Applicable

Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis
Assiut University30 enrolled2 locationsNCT05842681
Recruiting
Phase 2

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.340 enrolled52 locationsNCT06951217
Recruiting
Phase 1

Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects

Pulmonary Fibrosis
Guangdong Hengrui Pharmaceutical Co., Ltd20 enrolled1 locationNCT07229716
Recruiting

Role of Genetic Factors in the Development of Lung Disease

AsthmaCystic FibrosisPulmonary Fibrosis+2 more
National Heart, Lung, and Blood Institute (NHLBI)3,500 enrolled2 locationsNCT00001532
Recruiting
Phase 2

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics120 enrolled9 locationsNCT06968845
Recruiting
Phase 3

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Progressive Pulmonary FibrosisInterstitial Lung Disease
United Therapeutics698 enrolled152 locationsNCT05943535
Recruiting
Phase 2

A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
Sunshine Lake Pharma Co., Ltd.110 enrolled1 locationNCT05139719
Recruiting
Phase 2

Advanced Imaging for Pulmonary Fibrosis

Pulmonary Fibrosis
Peter Caravan60 enrolled1 locationNCT06532071
Recruiting
Phase 3

Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF

Idiopathic Pulmonary Fibrosis (IPF)
Sunshine Lake Pharma Co., Ltd.472 enrolled1 locationNCT07082842
Recruiting
Phase 1

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Mannkind Corporation24 enrolled8 locationsNCT07344558
Recruiting
Phase 1

NAL ER IPF Respiratory Function and Safety Study

Idiopathic Pulmonary Fibrosis
Trevi Therapeutics10 enrolled2 locationsNCT07036029
Recruiting
Phase 2

Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis
AbbVie165 enrolled6 locationsNCT07230288
Recruiting
Not Applicable

Validation of the C-mo System - Cough Monitoring

AsthmaChronic Obstructive Pulmonary DiseaseIdiopathic Pulmonary Fibrosis+5 more
Cough Monitoring Medical Solutions300 enrolled8 locationsNCT05989698
Recruiting
Phase 2

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

Progressive Pulmonary FibrosisInterstitial Lung DiseasePulmonary Fibrosis+4 more
Avalyn Pharma Inc.375 enrolled152 locationsNCT06329401
Recruiting
Phase 2

AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.160 enrolled3 locationsNCT07194382
Recruiting
Phase 2

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis
Mediar Therapeutics164 enrolled65 locationsNCT06967805